Evotec SE (NASDAQ:EVO – Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 191,400 shares, a drop of 8.6% from the August 15th total of 209,500 shares. Based on an average daily volume of 90,000 shares, the short-interest ratio is currently 2.1 days. Approximately 0.1% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on EVO. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. HC Wainwright lowered their price target on shares of Evotec from $11.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Finally, Morgan Stanley lowered shares of Evotec from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $15.00 to $6.00 in a report on Monday, July 29th.
Get Our Latest Analysis on EVO
Institutional Trading of Evotec
Evotec Stock Performance
Shares of Evotec stock remained flat at $3.64 during trading hours on Wednesday. 18,637 shares of the stock were exchanged, compared to its average volume of 105,792. The business’s 50 day moving average price is $3.88 and its 200 day moving average price is $5.20. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83. Evotec has a one year low of $2.85 and a one year high of $12.00.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
- Five stocks we like better than Evotec
- Using the MarketBeat Dividend Tax Calculator
- How Much Can You Make in Stocks in One Month?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- This Is the Top Large-Cap Stock Insiders Are Buying
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.